FCN2

Across TCGA pan-cancer cohorts, FCN2 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated FCN2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher FCN2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated FCN2 expression acts as an unfavorable survival marker.

PDAC, LUAD, and GBM are the cancer types where FCN2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	All	0.366	0.716	.003	19	view →
LUAD	OS	Quartile	III,IV	0.237	0.861	.003	19	view →
GBM	DFS	Median	All	0.256	0.492	.001	8	view →
LSCC	DFS	Quartile	II,III,IV	0.834	1.000	.013	5	view →
CCRCC	OS	Median	II,III,IV	0.635	0.825	.012	2	view →
UCEC	OS	Median	All	0.904	0.986	.034	2	view →
HNSC	DFS	Quartile	III,IV	0.468	0.809	.010	2	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

FCN2–PDAC (DFS)

Open the PDAC breakdown →